Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 | P11926 | 1/20 | 0.36 |
| ▸ | ITPR3 | Q14573 | 1/20 | 0.36 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL27942868 | 0.98 | ITPR3 (0.35) | ODC1ITPR3ITPR1LPAR3LPAR2 | |
| Dodecylamine SCHEMBL11084017 | 0.77 | LPAR3 (0.57) | LPAR3LPAR2TSHR | |
| Dodecylamine SCHEMBL11065806 | 0.77 | LPAR3 (0.62) | LPAR3LPAR2TSHR | |
| SCHEMBL28089409 | 0.76 | — | — | |
| SCHEMBL27618256 | 0.76 | LPAR2 (0.33) | ITPR3ITPR1LPAR3LPAR2 | |
| Water SCHEMBL28794135 | 0.74 | LPAR2 (0.32) | ITPR3ITPR1LPAR3LPAR2 | |
| SCHEMBL12819009 | 0.74 | LPAR3 (0.44) | LPAR3LPAR2LMNABLMTSHR | |
| SCHEMBL3501699 | 0.74 | — | — | |
| SCHEMBL5585483 | 0.72 | — | — | |
| SCHEMBL6933398 | 0.71 | LPAR3 (0.61) | LPAR3LPAR2LMNABLMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100365001-C | Synthesis method of 3-amino propylomine ethyl thio phosphoric acid | INST OF RADIATION AND RADIOMED (CN) | 2008-01-30 | — | — | CN | claimed |
| CN-1752092-A | The synthetic method of 3-aminopropylaminoethylthiophosphoric | INST OF RADIATION AND RADIOMED (CN) | 2006-03-29 | — | — | CN | claimed |
| CN-119752394-A | Aqueous polyurethane adhesive, preparation method and application thereof in lithium ion battery | 万华化学集团电池科技有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-102260288-B | Synthesis method of 3-amino-propyl aminoethyl thiophosphate trihydrate | CHENGDU DAYOUDE PHARMACEUTICAL CO LTD | 2014-02-26 | — | — | CN | disclosed |
| CN-102260288-A | Synthesis method of 3-amino-propyl aminoethyl thiophosphate trihydrate | — | 2011-11-30 | — | — | CN | disclosed |
| CN-100365001-C | Synthesis method of 3-amino propylomine ethyl thio phosphoric acid | INST OF RADIATION AND RADIOMED (CN) | 2008-01-30 | — | — | CN | disclosed |
| CN-100365001-C | Synthesis method of 3-amino propylomine ethyl thio phosphoric acid | INST OF RADIATION AND RADIOMED (CN) | 2008-01-30 | — | — | CN | disclosed |
| CN-1752092-A | The synthetic method of 3-aminopropylaminoethylthiophosphoric | INST OF RADIATION AND RADIOMED (CN) | 2006-03-29 | — | — | CN | disclosed |
| CN-1752001-A | The preparation method of sodium thiophosphate | INST OF RADIATION AND RADIOMED (CN) | 2006-03-29 | — | — | CN | disclosed |
| US-5902610-A | ADMINISTERING WITH OR WITHOUT CISPLATIN IN THE SAME FORMULATION, TO REDUCE TOXIC SIDE EFFECTS OF CISPLATIN IN CANCER THERAPY AND POTENTIATE ITS ANTITUMOR ACTIVITY | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-05-11 | — | — | US | disclosed |
| US-5866617-A | AQUEOUS SOLUTION FOR ADMINISTRATION TO PATIENTS ALSO RECEIVING CISPLATIN; REDUCED SIDE EFFECTS, INCREASED ANTITUMOR ACTIVITY | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5866615-A | LYOPHILIZED FORMULATION WITH ANTICANCER AGENTS; REDUCED SIDE EFFECTS, INCREASED ACTIVITY | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5866169-A | LYOPHILIZED FORMULATION WITH CISPLATIN; REDUCED SIDE EFFECTS, INCREASED ANTITUMOR ACTIVITY | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1999-02-02 | — | — | US | disclosed |
| US-5789000-A | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1998-08-04 | — | — | US | disclosed |